Protein Biosynthesis Interference in Disease offers a thorough discussion and overview of protein biosynthesis interference, its mechanisms of action, and influence over disease processes. This book examines the role of protein biosynthesis interference in Alzheimer's and other neurodegenerative conditions, cancer and inflammatory disorders, with specific attention paid to the biochemical dynamics of tryptamine, biogenic amines and aminoacyl-tRNA synthetases in these pathologies. Methods of regulating protein translation and interference mechanisms, including gene therapy, are presented,…mehr
Protein Biosynthesis Interference in Disease offers a thorough discussion and overview of protein biosynthesis interference, its mechanisms of action, and influence over disease processes. This book examines the role of protein biosynthesis interference in Alzheimer's and other neurodegenerative conditions, cancer and inflammatory disorders, with specific attention paid to the biochemical dynamics of tryptamine, biogenic amines and aminoacyl-tRNA synthetases in these pathologies. Methods of regulating protein translation and interference mechanisms, including gene therapy, are presented, empowering biochemists, molecular biologists, disease researchers, and health professionals to understand the underlying factors of protein disease and improve patient outcomes.
Dr. Paley is Cofounder of the nonprofit Stop Alzheimers Corp and Founder of Expert Biomed, Inc. She holds a PhD degree in biology with specialization in molecular biology from the Engelhardt Institute of Molecular Biology of the Russian Academy of Sciences in the Laboratory of Lev L. Kisselev. Dr. Paley's research focuses mainly on protein biosynthesis in biology and diseases and is conducted in collaboration with Harvard University, Brandeis University, the University of Miami, Tel Aviv University, the Institut des Vaisseaux et du Sang (Paris, France), and the University of Texas at San Antonio. She is Adjunct Professor at Nova Southeastern University, FL, United States, and is inventor in patents issued and pending.
Inhaltsangabe
1. Introduction2. Tryptamine in the diet, human microbiome, tRNA aminoacylation-protein biosynthesis, host-microbiota metabolic interactions3. Dimethyltryptamine, methyltryptamine, hallucinations and metals4. Psychoactive effects and toxicity of tryptamine, N-methyltryptamine (NMT) and N, N-dimethyltryptamine (DMT): quantification methods5. Tryptamine in renal pathologies and in pregnancy6. Tryptophanyl-tRNA synthetase (TrpRS) inhibition or TrpRS gene (WARS) mutations and deletion result to TrpRS deficiency and pathologies7. Tryptamine in liver diseases and alcohol abuse8. Tryptamine and tyramine in tobacco smoking9. Tryptamine and other biogenic amines in human vaginal samples10. Tryptamine and tryptophan in human fecal samples: diet alters tryptamine levels11. Tryptamine in human noncataractous and cataractous eye lenses12. Tryptamine toxicity in rats, adrenalectomy, toxicity prevention13. Microorganisms: the natural producers of tryptamine in food14. Human gut bacterial sequence associated with Alzheimer's disease and biogenic amines15. Disease, factors and condition associated with Alzheimer's disease (AD) and dementia support a concept that AD is a widespread systemic disorder16. Arterial hypertension in comorbidity in dementia and Alzheimer's disease, tryptamine in metabolic syndrome17. Whole blood viscosity: biogenic amines, dementia and Alzheimer's disease18. Tryptamine and aminoacyl-tRNAs in sleep-wake and circadian disruptions19. Senile plaques and/or neurofibrillary tangles in brain of non-demented individuals20. Historical perspectives and future research directions21. Tryptamine content and effects in humans and animals22. Link protein half-lives to neurodegeneration: tryptamine treatment effects23. Alzheimer's disease human gut microbiome associated sequence (ADAS): predictive disease modeling with ADAS: generating ADAS variants from human samples24. Tryptamine and other biogenic amines (BA) as modified and degradable factors25. Tryptamine and TrpRS in cancer and other conditions26. Experimental procedures: tryptophanyl-tRNA synthetase (TrpRS) characterization27. Tryptophanyl-tRNA synthetase (TrpRS) in phosphosignaling28. Tryptophanyl-tRNA synthetase antigenic epitopes and mimotpes29. Interactomes: tryptophanyl-tRNA synthetase forms and other aminoacyl-tRNA synthetases30. Tryptophanyl-tRNA synthetase in cell and organism survival31. Tryptophanyl-tRNA synthetase sharing epitopes32. Tryptamine and Tryptophanyl-tRNA synthetase in microvesicles, multivesicular bodies, and exosomes33. Tryptophanyl-tRNA synthetase and tryptamine in protein kinase and cancer pathways34. Global protein biosynthesis and aminoacyl-tRNA synthetase family
1. Introduction2. Tryptamine in the diet, human microbiome, tRNA aminoacylation-protein biosynthesis, host-microbiota metabolic interactions3. Dimethyltryptamine, methyltryptamine, hallucinations and metals4. Psychoactive effects and toxicity of tryptamine, N-methyltryptamine (NMT) and N, N-dimethyltryptamine (DMT): quantification methods5. Tryptamine in renal pathologies and in pregnancy6. Tryptophanyl-tRNA synthetase (TrpRS) inhibition or TrpRS gene (WARS) mutations and deletion result to TrpRS deficiency and pathologies7. Tryptamine in liver diseases and alcohol abuse8. Tryptamine and tyramine in tobacco smoking9. Tryptamine and other biogenic amines in human vaginal samples10. Tryptamine and tryptophan in human fecal samples: diet alters tryptamine levels11. Tryptamine in human noncataractous and cataractous eye lenses12. Tryptamine toxicity in rats, adrenalectomy, toxicity prevention13. Microorganisms: the natural producers of tryptamine in food14. Human gut bacterial sequence associated with Alzheimer's disease and biogenic amines15. Disease, factors and condition associated with Alzheimer's disease (AD) and dementia support a concept that AD is a widespread systemic disorder16. Arterial hypertension in comorbidity in dementia and Alzheimer's disease, tryptamine in metabolic syndrome17. Whole blood viscosity: biogenic amines, dementia and Alzheimer's disease18. Tryptamine and aminoacyl-tRNAs in sleep-wake and circadian disruptions19. Senile plaques and/or neurofibrillary tangles in brain of non-demented individuals20. Historical perspectives and future research directions21. Tryptamine content and effects in humans and animals22. Link protein half-lives to neurodegeneration: tryptamine treatment effects23. Alzheimer's disease human gut microbiome associated sequence (ADAS): predictive disease modeling with ADAS: generating ADAS variants from human samples24. Tryptamine and other biogenic amines (BA) as modified and degradable factors25. Tryptamine and TrpRS in cancer and other conditions26. Experimental procedures: tryptophanyl-tRNA synthetase (TrpRS) characterization27. Tryptophanyl-tRNA synthetase (TrpRS) in phosphosignaling28. Tryptophanyl-tRNA synthetase antigenic epitopes and mimotpes29. Interactomes: tryptophanyl-tRNA synthetase forms and other aminoacyl-tRNA synthetases30. Tryptophanyl-tRNA synthetase in cell and organism survival31. Tryptophanyl-tRNA synthetase sharing epitopes32. Tryptamine and Tryptophanyl-tRNA synthetase in microvesicles, multivesicular bodies, and exosomes33. Tryptophanyl-tRNA synthetase and tryptamine in protein kinase and cancer pathways34. Global protein biosynthesis and aminoacyl-tRNA synthetase family
Es gelten unsere Allgemeinen Geschäftsbedingungen: www.buecher.de/agb
Impressum
www.buecher.de ist ein Shop der buecher.de GmbH & Co. KG Bürgermeister-Wegele-Str. 12, 86167 Augsburg Amtsgericht Augsburg HRA 13309
